Published in Neurology on February 01, 1992
Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation. J Neurol Neurosurg Psychiatry (1994) 0.99
Epstein-Barr virus infection of human astrocyte cell lines. J Virol (1999) 0.91
An attempt to investigate the presence of Epstein Barr virus in multiple sclerosis and normal control brain tissue. J Neurol (2007) 0.91
Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. Am J Pathol (2013) 0.90
Multiple sclerosis and Epstein-Barr virus. Can J Infect Dis (2002) 0.76
Synaptic Plasticity and Neurological Disorders in Neurotropic Viral Infections. Neural Plast (2015) 0.75
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet (1987) 3.79
Stereotactic location and excision of seizure focus with xenon-enhanced CT. AJNR Am J Neuroradiol (1995) 3.57
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol (1981) 3.15
Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology (1987) 3.11
Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol (1991) 2.80
Relapsing transverse myelitis. Neurology (1991) 2.65
Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature (1974) 2.55
Ataxia-telangiectasia. Medicine (Baltimore) (1972) 2.50
Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature (1988) 2.27
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol (1990) 2.07
Myelopathic neurosarcoidosis: diagnostic value of enhanced MRI. Neurology (1991) 2.06
Further studies on the specificity of presumed immune associations of myasthenia gravis and consideration of possible pathogenic implications. Ann N Y Acad Sci (1966) 2.02
Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol (1991) 2.00
Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature (1984) 1.95
Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis. Nature (1993) 1.89
Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest (1981) 1.84
A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med (1991) 1.84
Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol (1995) 1.76
Nuclear magnetic resonance imaging in multiple sclerosis. Ann Neurol (1983) 1.75
Multiple sclerosis (first of two parts). N Engl J Med (1982) 1.72
Experimental allergic encephalomyelitis: enhancement of cell-mediated transfer by concanavalin A. J Immunol (1977) 1.58
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol (1993) 1.58
Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol (1985) 1.52
Impaired lymphocyte transformation in ataxia-telangiectasia in part due to a plasma inhibitory factor. J Immunol (1969) 1.51
Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol (1992) 1.50
Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int Immunol (1992) 1.43
Immunoglobulin A production in ataxia telangiectasia. Science (1965) 1.41
Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol (1992) 1.40
An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med (1970) 1.38
Immunoglobulin metabolism in ataxia telangiectasia. J Clin Invest (1968) 1.38
Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 1.35
Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J x PL/J)F1 mice by myelin basic protein and its peptides: localization of a second encephalitogenic determinant. J Immunol (1983) 1.35
The germline repertoire of T cell receptor beta-chain genes in patients with chronic progressive multiple sclerosis. J Neuroimmunol (1989) 1.32
Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin. Nature (1981) 1.30
Contact sensitivity in the pig. Immunology (1973) 1.30
Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med (1975) 1.28
Immunological studies in tropical spastic paraparesis. Ann Neurol (1990) 1.26
Recurrent experimental allergic encephalomyelitis in the Lewis rat. J Immunol (1974) 1.26
Cell type-specific regulation of major histocompatibility complex (MHC) class I gene expression in astrocytes, oligodendrocytes, and neurons. Glia (1993) 1.25
A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology (1984) 1.24
Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab Invest (1980) 1.24
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler (2000) 1.23
The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology (1994) 1.21
Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides. Science (1973) 1.21
Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol (1993) 1.20
Lymph node function and lymphocyte circulation in the pig. Adv Exp Med Biol (1973) 1.20
Relapsing murine experimental allergic encephalomyelitis induced by myelin basic protein. J Immunol (1983) 1.20
Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol (1990) 1.18
Thymic epithelial cell contains acetylcholine receptor. Lancet (1977) 1.18
Multiple sclerosis (second of two parts). N Engl J Med (1982) 1.18
Adoptively transferred chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Neuropathologic analysis. Lab Invest (1984) 1.17
Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes. J Immunol (1993) 1.15
Immune response of Lewis rats to peptide C1 (residues 68-88) of guinea pig and rat myelin basic proteins. J Exp Med (1977) 1.15
Brain stem tumors of childhood and adolescence. Am J Dis Child (1970) 1.15
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (2006) 1.15
Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol (1988) 1.14
Presentation of myelin basic protein by murine cerebral vascular endothelial cells. J Immunol (1985) 1.11
Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab Invest (1982) 1.11
Scrapie in immunologically deficient mice. Nature (1971) 1.10
The immune response against myelin basic protein in two strains of rat with different genetic capacity to develop experimental allergic encephalomyelitis. J Exp Med (1975) 1.09
Recurrent herpes simplex encephalitis: recovery of virus after Ara-A treatment. Ann Neurol (1983) 1.08
Human cellular immune response to measles virus polypeptides. J Virol (1984) 1.07
Purification of measles virus with preservation of infectivity and antigenicity. J Gen Virol (1979) 1.06
Cellular immune response to measles, mumps, and vaccinia viruses in multiple sclerosis. Ann Neurol (1979) 1.06
Astrocytes: auxiliary cells for immune responses in the central nervous system? Immunol Today (1990) 1.05
Encephalitogenic activity of guinea pig myelin basic protein in the SJL mouse. J Immunol (1982) 1.05
Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet (1992) 1.05
Immune reactivity of the purified hemagglutinin of measles virus. Infect Immun (1981) 1.04
Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol (1985) 1.04
Does myasthenic serum bind to the neuromuscular junction? Ann N Y Acad Sci (1966) 1.03
Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol (1993) 1.02
Evaluation of the structural proteins of the hamster neurotropic strain of measles virus with monoclonal antibodies. J Neuroimmunol (1986) 1.01
Systemic histiocytosis presenting as multiple sclerosis. Ann Neurol (1993) 1.01
Monospecific antibody to the haemagglutinin of measles virus. J Gen Virol (1980) 1.00
The response of human lymphocyte subpopulations to measles, mumps, and vaccinia viral antigens. J Immunol (1980) 0.99
HTLV-I-specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV-I-associated neurological disease. Ann Neurol (1992) 0.99
A preliminary trial of poly(I,C)-LC in multiple sclerosis. J Biol Response Mod (1985) 0.99
Biosynthesis of measles virus hemagglutinin in persistently infected cells. Arch Virol (1983) 0.99
Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology (1996) 0.98
Antibodies to the structural polypeptides of measles virus following acute infection and in SSPE. Clin Exp Immunol (1980) 0.98
Adoptive transfer of experimental allergic encephalomyelitis with activated spleen cells: comparison of in vitro activation by concanavalin a and myelin basic protein. Cell Immunol (1980) 0.98
Quantitation of IgG, IgA and IgM in the CSF by radioimmunoassay. Neurology (1978) 0.98
Immunopathology of the lesion in chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Cell Immunol (1986) 0.98
CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch Neurol (1980) 0.98
The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study. Mult Scler (1995) 0.98
Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology (1992) 0.97
Interaction between myelin basic protein-sensitized T lymphocytes and murine cerebral vascular endothelial cells. J Immunol (1986) 0.96
Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells. J Neuroimmunol (1993) 0.94
Experimental herpes simplex encephalitis. Treatment with pyrimidine nucleosides. Arch Neurol (1973) 0.93
Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 2. J Neuroimmunol (1993) 0.92
Central-nervous-system lesions detected by magnetic resonance imaging in an HTLV-1 antibody positive symptomless individual. Lancet (1987) 0.92
Measles virus-polypeptide specificity of the cytotoxic T-lymphocyte response in multiple sclerosis. J Neuroimmunol (1989) 0.92
Neurological and neuropsychological effects of cerebral spinal fluid shunting in children with assumed arrested ("normal pressure") hydrocephalus. J Neurol Neurosurg Psychiatry (1985) 0.92